NDA 050141 · King Pharms LLC
Bicillin L-A
Penicillin G Benzathine · Injection
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1952
Jun 27, 1952
Approved uses
5
Original approval plus efficacy supplements
Registered trials
802
170 Phase 3, 84 recruiting
FAERS reports
1,363
496 serious, 39 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING NOT FOR INTRAVENOUS USE. DO NOT INJECT INTRAVENOUSLY OR ADMIX WITH OTHER INTRAVENOUS SOLUTIONS. THERE HAVE BEEN REPORTS OF INADVERTENT INTRAVENOUS ADMINISTRATION OF PENICILLIN G BENZATHINE WHICH HAS BEEN ASSOCIATED WITH CARDIORESPIRATORY ARREST AND DEATH. Prior to administration of this drug, carefully read the WARNINGS , ADVERSE REACTIONS , and DOSAGE AND ADMINISTRATION sections of the labeling. WARNING NOT FOR INTRAVENOUS USE. DO NOT INJECT INTRAVENOUSLY OR ADMIX WITH OTHER INTRAVENOUS SOLUTIONS. THERE HAVE BEEN REPORTS OF INADVERTENT INTRAVENOUS ADMINISTRATION OF PENICILLIN G BENZATHINE WHICH HAS BEEN ASSOCIATED WITH CARDIORESPIRATORY ARREST AND DEATH. Prior to administration of this drug, carefully read the WARNINGS , ADVERSE REACTIONS , and DOSAGE AND ADMINISTRATION sections of the labeling.
What it is approved for
From the label in effect Jul 21, 2026.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections —Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea —Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis.
Mechanism: Mechanism of Action Penicillin G exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell-wall peptidoglycan, rendering the cell wall osmotically unstable.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 16, 1982 Supplement 210 · Efficacy
- Jun 22, 1955 Supplement 34 · Efficacy
- Feb 2, 1955 Supplement 29 · Efficacy
- Oct 21, 1954 Supplement 24 · Efficacy
- Jun 27, 1952 Original approval
2 products under this application
- BICILLIN L-A · PENICILLIN G BENZATHINE 300,000 UNITS/ML · INJECTABLE, INJECTION · Discontinued
- BICILLIN L-A · PENICILLIN G BENZATHINE 600,000 UNITS/ML · INJECTABLE, INJECTION · Prescription · TE BC
Clinical trials
Interventional ClinicalTrials.gov studies with "Penicillin G Benzathine" as an intervention, any sponsor and status, largest first.
- PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol]Pivotal-lookingNot yet recruiting
University of MelbourneAcademic, hospital or other
NCT06461429 · 100,000 participants (planned) · Start Nov 1, 2025 · Primary completion Dec 31, 2050
Drug: Erythromycin; Amoxicillin and Erythromycin and 4 more · For: Preterm Birth
- Evaluation of an Intensive 3-round MDA Strategy Towards Yaws EradicationPivotal-lookingCompleted
Lihir Medical CentreAcademic, hospital or other
NCT03490123 · 56,000 participants · Start Apr 16, 2018 · Primary completion Apr 1, 2020
Drug: R1-Total community treatment with azithromycin; R2-Total community treatment with azithromycin and 3 more · For: Yaws
Sites: Kavieng, Papua New Guinea
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New GuineaPivotal-lookingCompleted
Lihir Medical CentreAcademic, hospital or other
NCT01955252 · 16,000 participants · Start Mar 2013 · Primary completion May 2017
Drug: Azithromycin · For: Yaws
Sites: Londolovit, Papua New Guinea
- Staphylococcus Aureus Network Adaptive Platform TrialPivotal-lookingRecruiting
University of MelbourneAcademic, hospital or other
NCT05137119 · 8,000 participants (planned) · Start Feb 16, 2022 · Primary completion Dec 1, 2028
Drug: Cefazolin; Penicillin and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Houston, Texas; Garran, Australia; Blacktown, Australia · 161 sites in all
- Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTsPivotal-lookingCompleted
Mbarara University of Science and TechnologyAcademic, hospital or other
NCT00720811 · 6,456 participants · Start Oct 2009 · Primary completion Jan 2012
Drug: Artemether-lumefantrine combination; amoxycillin and 2 more · For: Malaria; Pneumonia
Sites: Saponé, Burkina Faso; Kassane, Ghana; Iganga, Uganda · 4 sites in all
- Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With SepsisPivotal-lookingRecruiting
Scandinavian Critical Care Trials GroupAcademic, hospital or other
NCT06184659 · 5,800 participants (planned) · Start Jun 26, 2025 · Primary completion Jun 30, 2028
Drug: Meropenem; Piperacillin/Tazobactam · For: Sepsis; Septic Shock
Sites: Copenhagen, Denmark · 2 sites in all
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- recalled product administered573
- drug hypersensitivity67
- injection site pain63
- off label use45
- embolia cutis medicamentosa44
- pain43
- drug ineffective33
- acute kidney injury31
- rash28
- diarrhoea26
- no adverse event25
- headache24
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 6 |
| 2006 | 6 |
| 2007 | 4 |
| 2008 | 17 |
| 2009 | 8 |
| 2010 | 51 |
| 2011 | 24 |
| 2012 | 24 |
| 2013 | 13 |
| 2014 | 10 |
| 2015 | 20 |
| 2016 | 30 |
| 2017 | 36 |
| 2018 | 34 |
| 2019 | 86 |
| 2020 | 68 |
| 2021 | 39 |
| 2022 | 88 |
| 2023 | 62 |
| 2024 | 62 |
| 2025 | 622 |
| 2026 | 43 |
Recalls
2 FDA enforcement reports for this application.
Jul 10, 2025 · Class II · Ongoing
CGMP Deviations; particulates identified during visual inspection
Jul 10, 2025 · Class II · Ongoing
CGMP Deviations; particulates identified during visual inspection
Shortages
FDA's drug shortage list.
Current · updated Nov 6, 2026
Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10). Other
Current · updated Nov 6, 2026
Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10). Other
Current · updated Nov 6, 2026
Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10). Other
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Bicillin L-A (Penicillin G Benzathine)
2024 spending
$4.5M
Beneficiaries
2,649
4,605 claims
Per beneficiary
$1,682
$145.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,130,430 |
| 2021 | $3,346,269 |
| 2022 | $3,738,217 |
| 2023 | $3,968,413 |
| 2024 | $4,456,479 |
Part B: Bicillin L-A (Penicillin G Benzathine) · HCPCS J0561
2024 spending
$2.3M
Beneficiaries
3,543
5,658 claims
Per beneficiary
$647
2024 ASP limit $23.02 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,007,911 |
| 2021 | $2,105,223 |
| 2022 | $2,434,151 |
| 2023 | $2,498,017 |
| 2024 | $2,292,754 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Azithromycin vs penicillin G benzathine for early syphilis: A meta-analysis of randomized controlled trials.
Li Y, Jiang G · Dermatol Ther 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Azithromycin vs. benzathine penicillin G for early syphilis: a meta-analysis of randomized clinical trials.
Bai ZG, Yang KH, Liu YL, et al. · Int J STD AIDS 2008 · Meta-Analysis, Systematic Review
- Azithromycin compared with penicillin G benzathine for treatment of incubating syphilis.
Hook EW, Stephens J, Ennis DM · Ann Intern Med 1999 · Clinical Trial, Comparative Study
- Efficacy of intramuscular penicillin in the eradication of group B streptococcal colonization at delivery.
Pinette MG, Thayer K, Wax JR, et al. · J Matern Fetal Neonatal Med 2005 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease.
Beaton A, Okello E, Rwebembera J, et al. · N Engl J Med 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Tolerability of IM penicillin G benzathine diluted or not with local anesthetics, or different gauge needles for syphilis treatment: a randomized clinical trial.
Estrada V, Santiago E, Cabezas I, et al. · BMC Infect Dis 2019 · Multicenter Study, Randomized Controlled Trial
Sponsor: King Pharms LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.